BPIC: A novel anti-tumor lead capable of inhibiting inflammation and scavenging free radicals

10Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

Inflammation has a critical role in the tumor progression, free radical damage can worse the status of patients in cancer condition. The anti-cancer agents capable of inhibiting inflammation and scavenging free radicals attract a lot of our interest. Aimed at the discovery of such anti-tumor agent, a novel intercalator, benzyl 1-[4-hydroxy-3-(methoxycarbonyl)-phenyl-9H-pyrido[3,4-b]indole-3-carboxylate (BPIC) was presented. The docking investigation of BPIC and doxorubicin towards the DNA (PDB ID: 1NAB) gave equal score and similar feature. The anti-proliferation assay of 8 cancer cells identified S180 cells had equal sensitivity to BPIC and doxorubicin. The anti-tumor assay defined the efficacy of BPIC been 2 folds higher than that of doxorubicin. At 1 μmol/kg of dose BPIC effectively inhibited xylene-induced ear edema and decreased the plasma TNF-α and IL-8 of the mice. BPIC scavenged OH O2 and NO free radicals in a concentration dependent manner and NO free radicals had the highest sensitivity. BPIC could be a novel anti-tumor lead capable of simultaneously inhibiting inflammation and scavenging free radicals.

Cite

CITATION STYLE

APA

Li, S., Wang, Y., Zhao, M., Wu, J., & Peng, S. (2015). BPIC: A novel anti-tumor lead capable of inhibiting inflammation and scavenging free radicals. Bioorganic and Medicinal Chemistry Letters, 25(5), 1146–1150. https://doi.org/10.1016/j.bmcl.2014.12.013

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free